---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-22-000157"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:38:28.325052+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Artivion Q2 revenue $80.3M (+6% GAAP, +9% CC); net loss widens to $4.3M

## Summary
- Revenue $80.3M vs $76.1M YoY; constant currency growth of 9%.
- GAAP net loss $4.3M ($0.11/sh) vs $2.2M ($0.06) YoY; non-GAAP net loss $1.3M ($0.03).
- Aortic stent graft revenue up 23% CC; On-X revenue up 12% CC; Asia Pacific +38% CC.
- Full-year 2022 constant currency revenue growth guidance reaffirmed at 9%-11%.
- Enrolled first patients in US AMDS clinical trial (PERSEVERE); expects FDA PMA approvals for PROACT Mitral and PerClot this year.

## SEC filing metadata
- accession: 0000784199-22-000157
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419922000157/0000784199-22-000157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419922000157/aort-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-22-000157
- JSON: https://secwatch.observer/filing/0000784199-22-000157.json
- Plain text: https://secwatch.observer/filing/0000784199-22-000157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.